6R-tetrahydrobiopterin treated PKU patients below 4 years of age: Physical outcomes, nutrition and genotype.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2015.03.007PMID 25882749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular epidemiology and genotype–phenotype correlation in phenylketonuria patients from South Spain

  2013cited by this paper
• The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria☆

  2013cited by this paper
• Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: impact on growth in PKU.

  2013cited by this paper
• Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride

  2013cited by this paper
• Risk factors for developing mineral bone disease in phenylketonuric patients.

  2013cited by this paper
• New evidence for assessing tetrahydrobiopterin (BH(4)) responsiveness.

  2012cited by this paper
• Optimising growth in phenylketonuria: current state of the clinical evidence base.

  2012cited by this paper
• Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria

  2012cited by this paper
• Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

  2012cited by this paper
• Effect of tetrahydrobiopterin on Phe/Tyr ratios and variation in Phe levels in tetrahydrobiopterin responsive PKU patients.

  2011cited by this paper
• Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria

  2011cited by this paper
• BH4 therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up

  2010cited by this paper
• Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence.

  2010cited by this paper
• Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).

  2010cited by this paper
• Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.

  2009cited by this paper
• Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria

  2009cited by this paper
• Spanish growth studies 2008. New anthropometric standards.

  2008cited by this paper
• Estudios españoles de crecimiento 2008. Nuevos patrones antropométricos

  2008cited by this paper
• Stability of blood phenylalanine levels and IQ in children with phenylketonuria.

  2008cited by this paper
• Protein and amino acid requirements in human nutrition.

  2007cited by this paper
• The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: Evaluation of response and subsequent treatment

  2007cited by this paper
• Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population.

  2005cited by this paper
• Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy.

  2005cited by this paper
• Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype.

  2001cited by this paper
• Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

  1999cited by this paper
• Growth and skeletal maturation in children with phenylketonuria

  1994cited by this paper
• The treatment of phenylketonuria. A decade of results.

  1966cited by this paper
• Growth and bone characteristics of phenylketonurics. Comparative analysis of treated and untreated phenylketonuric children.

  1966cited by this paper
• Phenylketonuria. II. Results of treatment of infants and young children. A report of 10 cases.

  1961cited by this paper

• European guidelines on diagnosis and treatment of phenylketonuria: First revision.

  2025cites this paper
• Unlocking The Efficacy of Tetrahydrobiopterin (BH4) Towards Metabolic Profile and Growth Status in Children with Phenylketonuria: A Meta Analysis

  2025cites this paper
• The clinical utility of short-term protein substitute use during intercurrent illness in BH4-responsive phenylketonuria.

  2025cites this paper
• Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers

  2024cites this paper
• Phenylalanine Tolerance over Time in Phenylketonuria: A Systematic Review and Meta-Analysis

  2023influential citation
• Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG).

  2023cites this paper
• Dietary Liberalization in Tetrahydrobiopterin-Treated PKU Patients: Does It Improve Outcomes?

  2022cites this paper
• Protein Substitute Requirements of Patients with Phenylketonuria on BH4 Treatment: A Systematic Review and Meta-Analysis

  2021influential citation
• Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta‐analysis of randomized controlled trials

  2019cites this paper
• Long-Term Growth in Phenylketonuria: A Systematic Review and Meta-Analysis

  2019cites this paper
• Treatment options and dietary supplements for patients with phenylketonuria

  2018cites this paper
• The relationship between dietary intake, growth and body composition in Phenylketonuria.

  2017cites this paper
• Fenilcetonuria de diagnóstico tardío y mutaciones asociadas en una familia ecuatoriana

  2017cites this paper
• Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness

  2015cites this paper
• Clinical Commissioning Policy : Sapropterin for Phenylketonuria ( all ages )

  year unknowncites this paper